← Return to Aromatase Inhibitors: Did you decide to go on them or not?

Discussion
Comment receiving replies
@callalloo

I'm just taking breastcancer.org's statement as written and pointing out that it is incorrect.

The OncotypeDX does not, in fact,
"predict(s) the likelihood of benefit from...radiation' therapy treatment" as stated in the excerpt you cited below. It does not make any radiation predictions at all.

"So, the Oncotype DX Breast Recurrence Score Test is both a prognostic test, since it provides more information about how likely (or unlikely) the breast cancer is to come back, and a predictive test, since it predicts the likelihood of benefit from chemotherapy or radiation therapy treatment. Studies have shown that Oncotype DX Breast Recurrence Score Test is useful for both purposes."

Jump to this post


Replies to "I'm just taking breastcancer.org's statement as written and pointing out that it is incorrect. The OncotypeDX..."

So I found an interesting study that says basically that Oncotype does not correlate with benefit or no benefit from radiation, so @callalloo you may be right in saying that this needs to be corrected at breastcancer.org.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285794/
2015
excerpt:
"Interestingly, radiation therapy was protective in patients with intermediate or low Oncotype DX scores but not in patients with high Oncotype DX scores (Table ​(Table2).2). In intermediate-risk patients, an HR of 0.72 (p = 1.5E−5) suggested that patients who underwent radiation therapy had longer OS compared to patients who did not undergo radiation therapy. Similarly, an HR of 0.76 (p = 2.0E−4) in low-risk patients suggested prolonged OS after the use of radiotherapy (Table ​(Table2).2). A similar observation was made when using BCSS although the association in low-risk patients did not reach statistical significance (Additional file 2 – Table 1)."

I should have had radiation afterall! Maybe you too!